DLA PIPER LLP (US)

Lobbying for BIOHAVEN PHARMACEUTICALS, INC. · A biopharmaceutical company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Connecticut · House · Senate · $60,000.00 income · posted Jan 16, 2026

Lobbying activity 1

Health Issues

Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.